News & Analysis on Clinical Trial Services & Contract Research And Development
Sanofi, Dietmar Berger
By Ben Hargreaves
- Last updated on
In an unusual move for a large pharma company, Sanofi revealed the identity of its new global head of development not through a press release but via Twitter.
Dietmar Berger, MD, PhD, joins #Sanofi as Head of Development, overseeing our clinical portfolio across all therapeutic areas and helping us bring transformative new medicines to patients. pic.twitter.com/ylwlwe4N0a
Berger returns to the big pharma fold after a one-year stint as global head of R&D at Atara Biotherapeutics. Prior to this, he had been SVP of Genentech’s global clinical development division for a six-year period.
In addition, he worked as VP of global clinical development at Bayer for two years and held a similar role at Amgen for four years during his 10-year tenure at the company.